Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
SUMOylation promotes extracellular vesicle–mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer
Changhao Chen, … , Jian Huang, Tianxin Lin
Changhao Chen, … , Jian Huang, Tianxin Lin
Published March 4, 2021
Citation Information: J Clin Invest. 2021;131(8):e146431. https://doi.org/10.1172/JCI146431.
View: Text | PDF
Research Article Cell biology Oncology

SUMOylation promotes extracellular vesicle–mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer

  • Text
  • PDF
Abstract

Small ubiquitin-like modifier (SUMO) binding (termed SUMOylation) emerged as the inducer for the sorting of bioactive molecules into extracellular vesicles (EVs), triggering lymphangiogenesis and further driving tumor lymph node (LN) metastasis, but the precise mechanisms remain largely unclear. Here, we show that bladder cancer (BCa) cell–secreted EVs mediated intercellular communication with human lymphatic endothelial cells (HLECs) through transmission of the long noncoding RNA ELNAT1 and promoted lymphangiogenesis and LN metastasis in a SUMOylation-dependent manner in both cultured BCa cell lines and mouse models. Mechanistically, ELNAT1 induced UBC9 overexpression to catalyze the SUMOylation of hnRNPA1 at the lysine 113 residue, which mediated recognition of ELNAT1 by the endosomal sorting complex required for transport (ESCRT) and facilitated its packaging into EVs. EV-mediated ELNAT1 was specifically transmitted into HLECs and epigenetically activated SOX18 transcription to induce lymphangiogenesis. Importantly, blocking the SUMOylation of tumor cells by downregulating UBC9 expression markedly reduced lymphatic metastasis in EV-mediated, ELNAT1-treated BCa in vivo. Clinically, EV-mediated ELNAT1 was correlated with LN metastasis and a poor prognosis for patients with BCa. These findings highlight a molecular mechanism whereby the EV-mediated ELNAT1/UBC9/SOX18 regulatory axis promotes lymphangiogenesis and LN metastasis in BCa in a SUMOylation-dependent manner and implicate ELNAT1 as an attractive therapeutic target for LN metastatic BCa.

Authors

Changhao Chen, Hanhao Zheng, Yuming Luo, Yao Kong, Mingjie An, Yuting Li, Wang He, Bowen Gao, Yue Zhao, Hao Huang, Jian Huang, Tianxin Lin

×

Figure 6

ELNAT1 is packaged into EVs by UBC9-induced SUMOylation of hnRNPA1.

Options: View larger image (or click on image) Download as PowerPoint

ELNAT1 is packaged into EVs by UBC9-induced SUMOylation of hnRNPA1.
(A)...
(A) Co-IP assay using anti-hnRNPA1 in UM-UC-3 cells. Red arrow indicates SUMO2. (B) Co-IP assay using anti-hnRNPA1 was performed to assess the conjunction of SUMO2 on hnRNPA1 in UM-UC-3 cells after UBC9 overexpression. (C) Schematic representation showing the predicted SUMO2 conjunct residues on hnRNPA1. (D) A co-IP assay using anti-His was performed to evaluate the conjunction of His-labeled SUMO2 on hnRNPA1 in UM-UC-3 cells after hnRNPA1K3R or hnRNPA1K113R mutation. (E) An IP assay was performed to evaluate His-labeled SUMO2 conjunction on hnRNPA1 in ELNAT1-overexpressing UM-UC-3 cells after UBC9 knockdown. (F) EV/cell ratio of RNAs in UM-UC-3 cells. (G) qRT-PCR was performed to analyze RNA expression in EVs secreted by UM-UC-3 cells after hnRNPA1 knockdown. (H) Assessment of ELNAT1 expression in BCa cell–secreted EVs after deletion of 610–680 nt of ELNAT1. (I) Analysis of ELNAT1 expression in BCa cell–secreted EVs after hnRNPA1K113R mutation. (J) Evaluation of ELNAT1 expression in EVs secreted by ELNAT1-overexpressing BCa cells after UBC9 knockdown. (K) ELNAT1 expression in EVs secreted by hnRNPA1-knockdown UM-UC-3 cells after hnRNPA1WT or hnRNPA1k113R overexpression was assessed by qRT-PCR. (L) Representative immunofluorescence images showing the accumulation of ELNAT1 into CD63-indicated MVBs in UM-UC-3 cells after hnRNPA1K113R mutation or UBC9 knockdown. Scale bar: 5 μm. A 1-way ANOVA followed by Dunnett’s test was used to assess statistical significance in F–K. Error bars showed the SD of 3 independent experiments. *P < 0.05 and **P < 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts